Immunotherapy and Hepatocellular Carcinoma: From Tumor-Immune Cell Interactions to Rational Therapeutic Strategies
Kizuki Yuza, Timothy M. Pawlik · 2026
Read Immunotherapy and Hepatocellular Carcinoma: From Tumor-Immune Cell Interactions to Rational Therapeutic Strategies by Kizuki Yuza, Timothy M. Pawlik (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13297510.txt.
Description
Why do some liver tumors answer immunotherapy while others shrug it off? Kizuki Yuza and Timothy M Pawlik organize the possible reasons in a 2026 review of hepatocellular carcinoma, using the cancer immunity cycle as their framework.
They sort failure points along that cycle: weak immune priming, poor cell trafficking into tumors, suppression by myeloid and stromal cells, and metabolic strain from low oxygen. Checkpoint drugs alone fix only certain breaks, so combinations work best when the partner drug targets the barrier that actually dominates a given tumor. Resistance, they note, can also arise from the tumor cells, the surrounding tissue, prior treatment, or the disease's cause, arguing for biomarker-guided choices.
Catalog record
| CREATOR | Kizuki Yuza, Timothy M. Pawlik |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63234 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |